
In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.
Children who are overweight or obese, especially girls, face an increased risk for developing gallstone disease compared with their normal-weight peers, according to research by Kaiser Permanente Southern California.






